PSPN (Persephin) encodes a neurotrophic factor belonging to the GDNF (glial cell line-derived neurotrophic factor) family of proteins. Located on chromosome 19p13.3, persephin is a secreted protein that promotes the survival, differentiation, and maintenance of various neuronal populations. The protein is particularly important for dopaminergic neurons, motor neurons, and peripheral neuronal populations, making it a molecule of significant interest for neurodegenerative disease research and therapeutic development.
Persephin was first identified in 1998 as the third member of the GDNF family, sharing structural homology and functional overlap with GDNF, neurturin, and artemin[1][2]. The name "persephin" derives from Greek mythology (Persephone, queen of the underworld), reflecting its discovered role in promoting neuronal survival. As a member of the GDNF family, persephin exerts potent neurotrophic effects on specific neuronal populations through activation of the RET tyrosine kinase receptor via GPI-anchored co-receptors.
| Persephin (PSPN) | |
|---|---|
| Gene Symbol | PSPN |
| Protein Name | Persephin |
| Chromosome | 19p13.3 |
| NCBI Gene ID | [5663](https://www.ncbi.nlm.nih.gov/gene/5663) |
| OMIM | 602565 |
| Ensembl ID | ENSG00000163389 |
| UniProt ID | [O60543](https://www.uniprot.org/uniprot/O60543) |
| Protein Family | GDNF family |
| Subcellular Location | Secreted extracellular |
| Associated Diseases | PD, ALS, Spinal Cord Injury |
The GDNF family includes four structurally related neurotrophic factors:
| Protein | Primary Receptors | Primary Target Neurons |
|---|---|---|
| GDNF | GFRα1/RET | Dopaminergic, motor neurons |
| Neurturin (NRTN) | GFRα2/RET | Dopaminergic, parasympathetic |
| Artemin (ARTN) | GFRα3/RET | Sympathetic neurons |
| Persephin (PSPN) | GFRα4/RET | Motor neurons, DRG neurons[3] |
Each family member signals through a bipartite receptor system consisting of a GPI-anchored co-receptor (GFRα) and the RET tyrosine kinase receptor.
The PSPN gene is located on chromosome 19p13.3 and encodes a preproprotein that undergoes proteolytic processing to generate the mature, secreted neurotrophic factor. The gene structure includes:
Persephin is a homodimeric secreted protein with:
Persephin signals through a bipartite receptor system[3:1]:
GFRα4 (GFRA4) — The primary GPI-anchored co-receptor for persephin. GFRα4 shows highest affinity for persephin among the GDNF family receptors and is expressed predominantly in motor neurons and specific peripheral neuronal populations. GFRα4 is unique among GFRα co-receptors in its specific distribution.
RET Tyrosine Kinase — The signal-transducing co-receptor. Upon persephin binding to GFRα4, RET is recruited and activated, initiating downstream intracellular signaling cascades. RET is expressed in most neurons that respond to GDNF family ligands.
Activated RET triggers multiple downstream signaling pathways[4]:
Persephin supports multiple neuronal populations:
Persephin is a promising therapeutic target for Parkinson's disease due to its potent neurotrophic effects on dopaminergic neurons[6][7]:
Neuroprotective mechanisms:
Therapeutic potential:
In ALS and related motor neuron disorders, persephin supports motor neuron survival[11]:
Research findings:
Persephin has shown promise in spinal cord injury models[12]:
Paradoxically, persephin also participates in pain modulation[13]:
The therapeutic application of persephin faces significant challenges:
| Challenge | Impact | Solutions |
|---|---|---|
| Blood-brain barrier | Limited CNS delivery | Intracerebral, intrathecal, viral vectors |
| Protein stability | Short half-life | Stabilized formulations, continuous infusion |
| Peripheral toxicity | Off-target effects | Cell-type specific promoters |
| Immunogenicity | Immune response | Humanized proteins, tolerance |
Persephin expression is temporally and spatially regulated:
| Brain Region | Expression Level | Functional Significance |
|---|---|---|
| Substantia Nigra | High | Dopaminergic neuron support |
| Spinal Cord | High | Motor neuron function |
| Brainstem | Moderate | Multiple neuronal populations |
| Cortex | Low-Moderate | Limited cortical effects |
| Hippocampus | Low | Sparse expression |
| Component | Role |
|---|---|
| GFRα4 | Co-receptor, ligand binding |
| RET | Tyrosine kinase, signal transduction |
| DOK proteins | Adaptor proteins |
| Enigma | Scaffolding protein |
| PI3K/Akt | Survival signaling |
| MAPK/ERK | Differentiation signaling |
| Model | Modification | Phenotype |
|---|---|---|
| PSPN knockout | Deletion | Viable, motor deficits |
| GFRα4 knockout | Deletion | Similar to PSPN KO |
| Conditional KO | Motor neuron-specific | Motor neuron loss |
Persephin connects to multiple NeuroWiki pages:
Milbrandt J, et al. Persephin: A neurotrophic factor for dopaminergic and motor neurons. Neuron. 1998. ↩︎
Baloh RH, et al. Persephin is the third member of the GDNF family. Proceedings of the National Academy of Sciences. 1998. ↩︎
Saarenpaa T, et al. GDNF family ligands and their receptors in the vertebrate nervous system. International Journal of Developmental Neuroscience. 2017. ↩︎ ↩︎
Zhao H, et al. RET receptor signaling in neuronal development. Developmental Neurobiology. 2022. ↩︎
Liu Y, et al. Persephin in enteric nervous system development. Developmental Biology. 2019. ↩︎
Multiple authors. Gene therapy for Parkinson's disease: Current status and future directions. Movement Disorders. 2022. ↩︎
Sullivan AM, et al. Persephin in 6-OHDA models of Parkinson's disease. Neurobiology of Disease. 2023. ↩︎
Chen W, et al. Combination therapy with GDNF and persephin. Molecular Neurobiology. 2021. ↩︎
Ibrahim Z, et al. Persephin gene therapy for Parkinson's disease. Molecular Therapy. 2023. ↩︎ ↩︎
Park H, et al. Small molecule RET agonists for CNS disorders. Journal of Medicinal Chemistry. 2022. ↩︎ ↩︎
Lin L, et al. GFRalpha4 and persephin in motor neuron diseases. Experimental Neurology. 2020. ↩︎
Meng X, et al. GDNF family ligands in spinal cord injury. Journal of Neurotrauma. 2018. ↩︎
Wang L, et al. Persephin and neuropathic pain. Pain. 2019. ↩︎
Kumar R, et al. Persephin delivery across the blood-brain barrier. Journal of Pharmaceutical Sciences. 2021. ↩︎